Neuropsychological Effects of Deep Brain Stimulation for Parkinson's Disease
Overview
Authors
Affiliations
Background: Putative changes of cognition after deep brain stimulation (DBS) in patients with Parkinson's disease (PD) are a matter of debate. The aim of this study was to assess cognitive abilities before and following bilateral subthalamic nucleus (STN) DBS and to review the available literature.
Methods: Twenty patients underwent bilateral DBS of the STN. Cognitive skills were assessed in a standardized fashion before and at least at 12 months after the surgical intervention.
Results: There was a significant decline of both semantic and phonematic verbal fluency and a mild trend for a deterioration of verbal memory after DBS. Mood, general cognitive screening, and visospatial abilities remained unchanged.
Conclusion: STN DBS in the treatment of PD has resulted in a significant reduction of motor symptoms and improved independence and quality of life in appropriately selected patients. However, it may have isolatable effects on verbal fluency and related function. Case series in the literature reported similar findings. Potential candidates for DBS should be counseled about the risk of mild cognitive declines.
Del Bene V, Martin R, Brinkerhoff S, Olson J, Nelson M, Marotta D Ann Neurol. 2024; 95(6):1205-1219.
PMID: 38501317 PMC: 11102318. DOI: 10.1002/ana.26903.
Del Bene V, Martin R, Brinkerhoff S, Olson J, Nelson M, Marotta D medRxiv. 2023; .
PMID: 36909562 PMC: 10002774. DOI: 10.1101/2023.02.27.23286478.
Surgical Advances in Parkinson's Disease.
Hvingelby V, Pavese N Curr Neuropharmacol. 2022; 22(6):1033-1046.
PMID: 36411569 PMC: 10964101. DOI: 10.2174/1570159X21666221121094343.
Deep brain stimulation effects on verbal fluency dissociated by target and active contact location.
John K, Wylie S, Dawant B, Rodriguez W, Phibbs F, Bradley E Ann Clin Transl Neurol. 2021; 8(3):613-622.
PMID: 33596331 PMC: 7951101. DOI: 10.1002/acn3.51304.
Recent Clinical Advances in Pharmacotherapy for Levodopa-Induced Dyskinesia.
Muller T, Mohr J Drugs. 2019; 79(13):1367-1374.
PMID: 31332769 DOI: 10.1007/s40265-019-01170-5.